BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lambrecht J, van Grunsven LA, Tacke F. Current and emerging pharmacotherapeutic interventions for the treatment of liver fibrosis. Expert Opin Pharmacother 2020;21:1637-50. [PMID: 32543284 DOI: 10.1080/14656566.2020.1774553] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Puengel T, Liu H, Guillot A, Heymann F, Tacke F, Peiseler M. Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2022;23:2668. [PMID: 35269812 DOI: 10.3390/ijms23052668] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 8.0] [Reference Citation Analysis]
2 Gallage S, García-beccaria M, Szydlowska M, Rahbari M, Mohr R, Tacke F, Heikenwalder M. The therapeutic landscape of hepatocellular carcinoma. Med 2021;2:505-52. [DOI: 10.1016/j.medj.2021.03.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Wang S, Tang C, Zhao H, Shen P, Lin C, Zhu Y, Han D. Network Pharmacological Analysis and Experimental Validation of the Mechanisms of Action of Si-Ni-San Against Liver Fibrosis. Front Pharmacol 2021;12:656115. [PMID: 34276360 DOI: 10.3389/fphar.2021.656115] [Reference Citation Analysis]
4 Yang J, Gong Y, Xu W, Li L, Shi Z, Wang Q, He Y, Zhang C, Luo C, Fang Z, Yang Y. Smad3 gene C-terminal phosphorylation site mutation exacerbates CCl4-induced hepatic fibrogenesis by promoting pSmad2L/C-mediated signaling transduction. Naunyn Schmiedebergs Arch Pharmacol 2021;394:1779-86. [PMID: 34191114 DOI: 10.1007/s00210-021-02114-1] [Reference Citation Analysis]
5 Zhang J, Liu Q, He J, Li Y. Novel Therapeutic Targets in Liver Fibrosis. Front Mol Biosci 2021;8:766855. [PMID: 34805276 DOI: 10.3389/fmolb.2021.766855] [Reference Citation Analysis]
6 Lambrecht J, Tacke F. Controversies and Opportunities in the Use of Inflammatory Markers for Diagnosis or Risk Prediction in Fatty Liver Disease. Front Immunol 2020;11:634409. [PMID: 33633748 DOI: 10.3389/fimmu.2020.634409] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
7 Ignat MV, Coldea TE, Salanță LC, Mudura E. Plants of the Spontaneous Flora with Beneficial Action in the Management of Diabetes, Hepatic Disorders, and Cardiovascular Disease. Plants (Basel) 2021;10:216. [PMID: 33498684 DOI: 10.3390/plants10020216] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Roohani S, Tacke F. Liver Injury and the Macrophage Issue: Molecular and Mechanistic Facts and Their Clinical Relevance. Int J Mol Sci 2021;22:7249. [PMID: 34298870 DOI: 10.3390/ijms22147249] [Reference Citation Analysis]
9 Delvescovo B, Tomlinson J, DeNotta S, Hodge E, Bookbinder L, Mohammed HO, Divers TJ. Bile Acids, Direct Bilirubin and Gamma-glutamyltransferase as Prognostic Indicators for Horses with Liver Disease in the Eastern United States: 82 Cases (1997-2019). J Equine Vet Sci 2021;105:103729. [PMID: 34607679 DOI: 10.1016/j.jevs.2021.103729] [Reference Citation Analysis]
10 Xue F, Lu J, Buchl SC, Sun L, Shah VH, Malhi H, Maiers JL. Coordinated signaling of activating transcription factor 6α and inositol-requiring enzyme 1α regulates hepatic stellate cell-mediated fibrogenesis in mice. Am J Physiol Gastrointest Liver Physiol 2021;320:G864-79. [PMID: 33728997 DOI: 10.1152/ajpgi.00453.2020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Lambrecht J, Tacke F. Acetyl-CoA Carboxylase Inhibition as a Therapeutic Tool in the Battle Against NASH: Hitting More Than Just One Mechanism? Cell Mol Gastroenterol Hepatol 2020;10:859-61. [PMID: 32730829 DOI: 10.1016/j.jcmgh.2020.07.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Sun C, Shi C, Duan X, Zhang Y, Wang B. Exosomal microRNA-618 derived from mesenchymal stem cells attenuate the progression of hepatic fibrosis by targeting Smad4. Bioengineered 2022;13:5915-27. [PMID: 35199612 DOI: 10.1080/21655979.2021.2023799] [Reference Citation Analysis]
13 Yang A, Yan X, Xu H, Fan X, Zhang M, Huang T, Li W, Chen W, Jia J, You H. Selective depletion of hepatic stellate cells-specific LOXL1 alleviates liver fibrosis. FASEB J 2021;35:e21918. [PMID: 34569648 DOI: 10.1096/fj.202100374R] [Reference Citation Analysis]
14 Zhang N, Wu Y, Zhong W, Xia G, Xia H, Wang L, Wei X, Li Y, Shang H, He H, Lin S. Multiple anti-non-alcoholic steatohepatitis (NASH) efficacies of isopropylidenyl anemosapogenin via farnesoid X receptor activation and TFEB-mediated autophagy. Phytomedicine 2022;102:154148. [DOI: 10.1016/j.phymed.2022.154148] [Reference Citation Analysis]
15 Boeckmans J, Gatzios A, Heymans A, Rombaut M, Rogiers V, De Kock J, Vanhaecke T, Rodrigues RM. Transcriptomics Reveals Discordant Lipid Metabolism Effects between In Vitro Models Exposed to Elafibranor and Liver Samples of NAFLD Patients after Bariatric Surgery. Cells 2022;11:893. [DOI: 10.3390/cells11050893] [Reference Citation Analysis]